Neuroblastoma patients' genomic and biological profile study

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational, investigator-initiated study collects biological samples (blood, tumor tissue, and/or bone marrow) from neuroblastoma patients across participating centers. Samples are centralized for centralized analysis, and data are recorded using paper-based forms with unique patient codes. Inclusion spans newly diagnosed to relapsed or refractory disease, with informed consent required. The study does not specify interventions or treatment changes but aims to characterize molecular and biological features. Geographic sites are pediatric centers in Italy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All patients diagnosed with neuroblastoma at AIEOP centers.
* Signed informed consent/assent provided by the subject and/or their parents or legal guardians.
* Age 0 to ≤ 31 years.
* Life expectancy \> 3 months.
* Availability of fresh tumor tissue and/or bone marrow and peripheral blood samples.

Exclusion Criteria:

* Absence of signed informed consent/assent from the subject and/or their parents or legal guardians.
* Life expectancy \< 3 months.

Where it's running

• Azienda Ospedali Riuniti Presidio "G. Salesi", SOS Oncoematologia pediatrica
  Ancona, Italy Recruiting
• AO Policlinico, Dipartimento di pediatria
  Bari, Italy Recruiting
• Ospedale Papa Giovanni XXIII USS Oncoematologia Pediatric
  Bergamo, Italy Recruiting
• Oncologia ed Ematologia Pediatrica "Lalla Seragnoli" Clinica Pediatrica Policlinico Sant'Orsola Malpighi
  Bologna, Italy Recruiting
• Spedali civili, presidio Ospedale dei Bambini oncoematologia pediatrica e TMO
  Brescia, Italy Recruiting
• SC Oncoematologia Pediatrica e Patologia della Coagulazione, Ospedale Pediatrico Microcitemico "Antonio Cao", Azienda Ospedaliera Brotzu
  Cagliari, Italy Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CIML-NK Cells to Treat Neuroblastoma in Relapsed or Refractory Patients

  We’re testing whether donor-derived cytokine-induced memory-like NK cells can be safely given with dinutuximab to kids and young adults whose neuroblastoma has come back or not responded to treatment.

  Recruiting Phase 2 Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio · NCT07635056

• Becotatug Vedotin for EGFR-positive relapsed, refractory, or metastatic pediatric solid tumors

  This trial will test Becotatug Vedotin, an EGFR-targeted antibody-drug conjugate, to see if it is safe and helps children aged 2–18 with EGFR-positive relapsed, refractory, or metastatic solid tumors.

  Recruiting Phase 1 Sun Yat-sen University · Guangzhou, Guangdong · NCT07584499

• Tracking tumor DNA over time in neuroblastoma

  This project tests whether regular blood tests measuring circulating tumor DNA and molecular residual disease can track disease status and detect relapse earlier in children with neuroblastoma.

  Recruiting Sun Yat-sen University · Guangzhou, Guangdong · NCT07516678

• Anti-GD2-800CW imaging to highlight neuroblastoma during surgery

  This trial will test whether a fluorescent antibody called anti-GD2-800CW can safely help surgeons see and remove neuroblastoma in children ages 1 to 18.

  Recruiting Phase 1/2 Princess Maxima Center for Pediatric Oncology · Utrecht · NCT07399821

• B7-H3 CAR T cells for relapsed or refractory solid tumors in children and young adults

  This study tests a new B7-H3 CAR T cell therapy to see if it is safe and can help kids and young adults whose solid tumors have come back or stopped responding to standard treatments.

  Recruiting Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07358260

• NET- and somatostatin-targeted PET/SPECT imaging to find and stage neuroblastoma and pheochromocytoma/paraganglioma

  This study will try different PET and SPECT tracers to see if they can accurately find and stage tumors in children and adults with neuroblastoma or pheochromocytoma/paraganglioma.

  Recruiting Nanjing First Hospital, Nanjing Medical University · Nanjing, Jiangsu · NCT07195500

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.